HC Wainwright Has Optimistic Opinion of Insmed Q3 Earnings

Insmed, Inc. (NASDAQ:INSM) – Equities researchers at HC Wainwright lifted their Q3 2026 earnings estimates for Insmed in a research report issued on Monday, October 12th. HC Wainwright analyst A. Fein now expects that the biopharmaceutical company will post earnings of ($0.13) per share for the quarter, up from their prior estimate of ($0.31). HC Wainwright has a “Buy” rating and a $220.00 price objective on the stock. The consensus estimate for Insmed’s current full-year earnings is ($1.84) per share. HC Wainwright also issued estimates for Insmed’s Q4 2026 earnings at ($0.08) EPS and FY2026 earnings at ($1.26) EPS.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.61. Insmed had a negative net margin of 76.94% and a negative return on equity of 123.94%. The business had revenue of $425.49 million during the quarter, compared to the consensus estimate of $395.50 million. During the same quarter in the prior year, the firm posted ($1.70) earnings per share. The company’s revenue was up 296.1% compared to the same quarter last year.

INSM has been the subject of several other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Insmed in a research note on Friday, July 17th. Mizuho set a $192.00 price target on Insmed in a research report on Tuesday, June 16th. Cantor Fitzgerald reiterated an “overweight” rating and set a $235.00 price target on shares of Insmed in a research report on Tuesday, July 28th. Wolfe Research lowered Insmed from an “outperform” rating to a “peer perform” rating in a report on Monday. Finally, JPMorgan Chase & Co. cut their price objective on Insmed from $179.00 to $175.00 and set an “overweight” rating for the company in a research report on Monday, August 10th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $200.30.

Insmed Price Performance

NASDAQ:INSM opened at $96.79 on Wednesday. Insmed has a 52 week low of $90.39 and a 52 week high of $212.75. The company has a quick ratio of 3.40, a current ratio of 3.72 and a debt-to-equity ratio of 0.74. The stock has a market capitalization of $21.14 billion, a PE ratio of -23.55 and a beta of 0.83. The stock’s 50-day moving average price is $120.16 and its 200-day moving average price is $119.10.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Reflection Asset Management acquired a new stake in Insmed in the 4th quarter worth about $30,000. CX Institutional purchased a new stake in Insmed during the 3rd quarter worth approximately $46,000. Whittier Trust Co. of Nevada Inc. raised its holdings in shares of Insmed by 86.6% during the first quarter. Whittier Trust Co. of Nevada Inc. now owns 444 shares of the biopharmaceutical company’s stock valued at $73,000 after acquiring an additional 206 shares during the last quarter. Harbor Investment Advisory LLC acquired a new position in shares of Insmed during the second quarter valued at approximately $52,000. Finally, Versant Capital Management Inc raised its holdings in shares of Insmed by 118.9% during the third quarter. Versant Capital Management Inc now owns 648 shares of the biopharmaceutical company’s stock valued at $74,000 after acquiring an additional 352 shares during the last quarter.

Insider Buying and Selling at Insmed

In other news, COO Roger Adsett sold 239,850 shares of Insmed stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $133.27, for a total value of $31,964,809.50. Following the sale, the chief operating officer owned 98,744 shares in the company, valued at $13,159,612.88. This trade represents a 70.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director David R. Brennan sold 25,000 shares of the business’s stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $124.00, for a total transaction of $3,100,000.00. Following the sale, the director directly owned 39,238 shares of the company’s stock, valued at $4,865,512. This represents a 38.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 2.10% of the company’s stock.

Insmed News Summary

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and maintained a $220 price target, implying substantial upside from recent trading levels. The firm also slightly raised its FY2027 EPS estimate to $1.63 from $1.62. Insmed’s Buy Rating Reaffirmed at HC Wainwright
• Positive Sentiment: Investors purchased 8,177 call options on Tuesday, more than triple the average volume of 2,676 contracts. The unusually high call activity may indicate increased speculative interest or expectations for a rebound, although options positioning does not guarantee future gains.
• Neutral Sentiment: Analyst coverage remains divided: HC Wainwright is bullish, while Wolfe Research moved to a more neutral stance. This disagreement may contribute to elevated volatility as investors reassess Insmed’s valuation and growth outlook. Analysts Offer Insights on Healthcare Companies
• Negative Sentiment: Wolfe Research downgraded Insmed from Outperform to Peer Perform, removing a bullish endorsement and likely pressuring the stock. The downgrade was highlighted as the main catalyst behind the shares’ decline. Insmed Shares Fall After Wolfe Research Downgrade

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for patients with serious and rare diseases. The company’s research and development activities center on pulmonary and inflammatory conditions, with an emphasis on diseases that have limited treatment options.

Insmed’s principal commercial product is ARIKAYCE liposomal, an inhaled formulation of amikacin used with a combination antibacterial regimen to treat refractory Mycobacterium avium complex lung disease in certain adult patients.